or Try an Advanced Search...

    Regeneron Stocks List

    Symbol Grade Name % Change
    ADVM F Adverum Biotechnologies, Inc. -2.94
    REGN C Regeneron Pharmaceuticals, Inc. 0.45
    SNY B Sanofi -0.94
    View As Page of Charts
    Related Industries: Biotechnology Drug Manufacturers - Major
    Related Stock Lists: Colorectal Cancer Macular Degeneration Pain Adverum Biotechnologies Angiogenesis Animal Health Antibodies Asthma Atopic Dermatitis Biopharmaceutical Biotechnology Bone Breakthrough Therapy Cac 40 Cancer Cardiovascular Disease Cartilage Cholesterol Chronic Kidney Disease Clinical Development

    Related ETFs - A few ETFs which own one or more of the above listed Regeneron stocks.

    Symbol Grade Name Weight
    IBBQ B Invesco Nasdaq Biotechnology ETF 9.54
    IBB C iShares Nasdaq Biotechnology Index Fund 8.24
    VIRS C Pacer BioThreat Strategy ETF 7.92
    BBH B Market Vectors Biotech ETF 7.69
    BIB C ProShares Ultra Nasdaq Biotechnology 6.51
    View all Regeneron ETFs...
    Compare ETFs
    Compare BBH to BIB Compare IBB to BBH Compare IBBQ to IBB

        Regeneron Stocks Recent News

        Date Stock Title
        May 24 SNY Zantac Verdict: Jury Finds No Link To Colon Cancer In Initial Trial, GSK And Boehringer Prevail In First Zantac Cancer Lawsuit
        May 24 REGN After UnitedHealth Cyberattack, Drug Distributor Cencora Notifies Americans' Health Information Stolen In Data Breach In February
        May 24 REGN Ireland – the jewel in the life sciences crown?
        May 24 REGN Regeneron (REGN) Announces Positive Data on Oncology Candidate
        May 23 REGN Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO
        May 23 SNY Sanofi reports positive data from Phase II asthma treatment trial
        May 23 REGN 3 Stocks That Have Turned $25,000 Into More Than $1 Million in 15 Years
        May 22 SNY Sanofi says asthma candidate rilzabrutinib buoyed by phase 2 results
        May 22 SNY Bristol-Myers, Sanofi liability in Hawaii Plavix litigation tops $900M
        May 22 SNY Hawaii Court Rules Against Bristol Myers, Sanofi In Blood Clot Drug Case, Increases Liability To $916M
        May 22 SNY First Advanced Oral Treatment For Asthma - Sanofi's Investigational Drug Shows Potential
        May 22 SNY Bristol Myers, Sanofi liability in Hawaii Plavix case grows to $916 million
        May 22 REGN Is Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Trading At A 48% Discount?
        May 22 SNY Better Buy: Inovio Pharmaceuticals vs. Novavax
        May 22 REGN Regeneron faces new biosimilar threats; an AI biotech lays off staff
        May 22 SNY 3 Things You Need to Know If You Buy Novavax Today
        May 22 SNY Sanofi enters partnership to enhance drug development using AI
        May 22 SNY Hawaii court orders drug companies to pay $916 million in Plavix blood thinner lawsuit
        May 21 SNY Sanofi (SNY) Signs Deal for AI-Powered Drug Development
        May 21 SNY ChatGPT Parent Open AI Partners With Sanofi, Formation Bio To Boost AI-Driven Drug Development
        Related Industries: Biotechnology Drug Manufacturers - Major
        Related Stock Lists: Colorectal Cancer Macular Degeneration Pain Adverum Biotechnologies Angiogenesis Animal Health Antibodies Asthma Atopic Dermatitis Biopharmaceutical Biotechnology Bone Breakthrough Therapy Cac 40 Cancer Cardiovascular Disease Cartilage Cholesterol Chronic Kidney Disease Clinical Development
        Regeneron

        Regeneron Pharmaceuticals, Inc. is a biotechnology company headquartered in Eastview, near Tarrytown, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities (thus the name), it branched out into the study of both cytokine and tyrosine kinase receptors.

        More about Regeneron
        Browse All Tags